FDA's June 15 Safety Alert On Unapproved GLP-1 Drugs: Counterfeits, Warm Shipments, And Dosing Errors

June 17, 2026

The FDA didn’t ban compounded GLP-1 drugs this week. It did something more practical: it laid out the ways patients get hurt when “semaglutide” or “tirzepatide” shows up as a cold-shipped vial from an online funnel with a checkout button, a dosing chart, and no real line of accountability.

In two mid‑June updates, the agency highlighted the risks it’s seeing in the wild—fraudulent labels, warm shipments, dosing mistakes that have landed people in the hospital—and reminded telehealth marketers that “compounded” is not a synonym for “generic.” FDA, June 15 is blunt about the marketing angle. FDA, June 15 is blunt about the patient-safety angle.

For clinicians, compounders, and patients trying to navigate shortages and affordability, the message is: the rules haven’t vanished just because demand exploded. And the enforcement surface is wider than most people realize—web copy, shipping practices, bulk API imports, and even what a label implies about who actually made the drug.

What changed this week: the FDA put the risk story in one place

Policy shifts are usually announced with a new regulation. This one is closer to a map. The FDA’s June 15 statement collects the failure modes it says are showing up with unapproved GLP‑1 drugs—especially compounded semaglutide and tirzepatide—and spells out what to watch for.

Three details matter for the peptide world:

• “Compounded” doesn’t mean “approved.” The FDA repeats that compounded drugs are not FDA‑approved and aren’t reviewed for safety, effectiveness, or quality before marketing. The statement is aimed at consumers, but it reads like a warning to every intermediary in the supply chain. FDA, June 15
• Some GLP‑1 adjacents are off-limits for compounding. The agency says retatrutide and cagrilintide “cannot be used in compounding under federal law.” It also notes these aren’t components of FDA‑approved drugs and haven’t been found safe and effective for any condition. FDA, June 15
• The FDA is treating bulk GLP‑1 APIs as a border problem. The statement points to Import Alert 66‑80, described as “Detention Without Physical Examination of Glucagon‑Like Peptide‑1 (GLP‑1) Receptor Agonist Bulk Drug Substances.” FDA Import Alerts by Publish Date

That last point is easy to miss if you’re focused on domestic compounding rules. But it matters because a large chunk of risk in the compounding ecosystem comes from the quality, identity, and custody of bulk ingredients—especially when a “research” supply chain quietly becomes a human-use supply chain.

Where the harm happens: labels, logistics, and dosing math

The most arresting part of the FDA’s June 15 statement isn’t legal at all. It’s operational. It reads like a list of the boring ways a drug becomes unsafe when it is assembled outside an approval system.

1) Fraudulent compounded GLP‑1 products

The FDA says it’s aware of fraudulent compounded semaglutide and tirzepatide with false label information—sometimes naming compounding pharmacies that don’t exist. In other cases, the label uses the name of a real licensed pharmacy that, based on information FDA gathered, “did not compound these products.” FDA, June 15

This isn’t just “counterfeit Ozempic” panic. It’s a custody problem. If you can’t reliably identify the actual compounder, you can’t audit sterility practices, validate cold-chain controls, or even know which jurisdiction’s pharmacy board might investigate. That is exactly what enforcement agencies look for when they decide whether the public is being misled.

2) Cold-chain failures in shipping

Injectable GLP‑1 drugs require refrigeration. The FDA says it has received complaints that compounded GLP‑1 drugs arrived warm or with inadequate ice packs, and it recommends patients not use any injectable GLP‑1 drug that arrives warm or improperly chilled. FDA, June 15

Cold-chain mistakes aren’t abstract. A peptide or peptide-like drug can degrade, aggregate, or lose potency with temperature excursions. Even if the molecule survives, the moment a patient has to wonder if it did, trust collapses—and so does any realistic way to monitor safety signals.

3) Dosing errors and “beyond-label” dosing

The FDA reports “multiple” adverse events—some requiring hospitalization—linked to dosing errors with compounded injectable semaglutide, including patients measuring the wrong amount and health care professionals miscalculating doses. It also describes reports tied to dosing beyond the FDA‑approved label (more product per dose, more frequent dosing, or faster titration), with some patients seeking medical attention for nausea, vomiting, diarrhea, abdominal pain, and constipation. FDA, June 15

This is where policy meets arithmetic. Approved pens and prefilled devices make dosing hard to mess up. A vial and a syringe bring dosing math back into the room. Telehealth platforms that behave like e-commerce can amplify that risk at scale.

4) Semaglutide salt forms

The FDA says some compounders may be using semaglutide salt forms (such as semaglutide sodium or semaglutide acetate) and notes these are different active ingredients than what’s used in approved drugs. The agency says it does not have information showing the salts have the same chemical and pharmacologic properties as the approved active ingredient and that it is not aware of any lawful basis for their use in compounding. FDA, June 15

For people who follow peptide markets, this is familiar. “Same name, different form” is a recurring trap. It’s also the kind of detail that becomes the hinge of enforcement: if the active ingredient is not what it’s represented to be, you’re no longer arguing over gray zones. You’re arguing over misbranding and adulteration.

Telehealth marketing is now a frontline enforcement target

The FDA’s separate June 15 page aimed at telehealth companies reads like a checklist of phrases to delete from a landing page. The agency says it is concerned about telehealth companies promoting compounded drugs with false or misleading claims and notes it has issued warning letters. FDA, June 15

Among the practices the FDA flags:

• Branding that implies the telehealth company is the compounder. FDA, June 15
• Calling a compounded drug “a generic” or “the same as” an FDA‑approved drug. FDA, June 15
• Claiming a compounded drug is FDA‑approved or evaluated for safety and effectiveness. FDA, June 15
• Claiming the drug is sourced from an “FDA‑approved” or “FDA‑licensed” facility (the FDA notes it does not approve or license facilities). FDA, June 15

This is the policy voice—short, declarative, unamused. It’s also a signal that enforcement isn’t limited to what’s in the vial. Messaging itself can make a product misbranded, and the FDA is telling companies it is actively reading promotional materials.

A concrete example: the FDA’s warning letter to FITISH

If you want to see what “false or misleading promotion” looks like in practice, the FDA’s June 8 warning letter to FITISH is a clean specimen.

In the letter, the FDA describes reviewing FITISH’s website and observing that it offered compounded semaglutide and tirzepatide. The FDA then points to two specific patterns:

• Label implication. The website displayed product labels that identified “FITISH,” which the FDA says suggests FITISH is the compounder “when in fact it is not.” FDA warning letter (FITISH), June 8
• “Active ingredient” claims that read like equivalence. The FDA cites statements such as “Semaglutide is the active ingredient in ozempic” and “Tirzepatide is the active ingredient in Mounjaro® and Zepbound®” and says these claims represent the compounded products as FDA‑approved or evaluated for safety and effectiveness when they have not. FDA warning letter (FITISH), June 8

The technicality here is instructive: the problem is not that semaglutide is an active ingredient in an approved product. The problem is the rhetorical leap a consumer might reasonably make when it is presented that way on a sales page. The FDA treats that leap as a misleading representation about approval and equivalence.

What this means for patients and clinicians

It’s tempting to treat all of this as an industry fight between pharma and compounding. That’s not what the FDA is describing. The agency is describing a patient‑safety signal, and it’s describing how that signal gets amplified by modern distribution.

For patients, the practical implications are boring and urgent:

• If you’re using a compounded injectable, treat temperature on arrival as a safety check, not an inconvenience. FDA, June 15
• Be skeptical of “too good to be true” pricing, brand‑like marketing, and platforms that don’t require a real prescription workflow. The FDA lists these as consumer red flags. FDA, June 15
• Ask directly: who compounded this, where, and under what standards? If nobody can answer clearly, that’s the answer. FDA, June 15

For clinicians, the issues are partly clinical and partly systems engineering:

• Vial‑based products shift dosing risk back onto the prescriber and the patient. If a patient is measuring doses, you may need to teach and verify technique.
• “Beyond-label” titration schedules may appear in telehealth protocols. The FDA is signaling it’s seeing adverse events where dosing goes past approved labeling. FDA, June 15
• Adverse event reporting may be incomplete. The FDA notes that state-licensed pharmacies that are not outsourcing facilities are not required by federal law to submit adverse event reports to FDA, so compounded-drug adverse events are likely underreported. FDA, June 15

That underreporting point should land with anyone trying to interpret post‑market safety signals. If the reporting pipeline is patchy, you can’t rely on absence of reports as reassurance.

Related PeptideKnow references

• Semaglutide — peptide-like GLP‑1 receptor agonist.
• Tirzepatide — dual GIP/GLP‑1 receptor agonist.
• Retatrutide — investigational triple agonist discussed by FDA in the context of unlawful compounding. FDA, June 15
• Weight loss & metabolic peptides — browse GLP‑1 and GLP‑1–adjacent peptides and analogs.
• PeptideKnow News — ongoing regulatory and industry coverage.

Frequently Asked Questions

Are compounded semaglutide or tirzepatide legal?

Compounding can be legal in specific circumstances, such as when a patient’s medical need can’t be met by an FDA‑approved drug or the approved drug is not commercially available. The FDA also emphasizes that compounded drugs are not FDA‑approved and aren’t reviewed for safety, effectiveness, or quality before marketing. FDA, June 15

Why does the FDA focus on telehealth marketing language?

The FDA says false or misleading promotion can keep patients from making informed decisions and can violate federal law. It specifically warns against describing compounded drugs as “generic,” implying FDA approval, or implying a telehealth company is the compounder. FDA, June 15

What is Import Alert 66‑80?

Import Alert 66‑80 is titled “Detention Without Physical Examination of Glucagon‑Like Peptide‑1 (GLP‑1) Receptor Agonist Bulk Drug Substances,” and it is listed in the FDA’s Import Alerts by publish date. FDA Import Alerts by Publish Date

What’s the issue with semaglutide salt forms?

The FDA notes that semaglutide sodium and semaglutide acetate are different active ingredients than the active ingredient used in FDA‑approved semaglutide products. The agency says it does not have information showing these salts have the same chemical and pharmacologic properties and says it is not aware of any lawful basis for their use in compounding. FDA, June 15

Sources (primary)

• FDA. “FDA’s Concerns with Unapproved GLP‑1 Drugs Used for Weight Loss.” Updated June 15, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
• FDA. “What to Know When Promoting Compounded Drugs.” June 15, 2026. https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs
• FDA. Warning Letter: “FITISH MARCS‑CMS 728280 — June 08, 2026.” Posted June 16, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitish-728280-06082026
• FDA Access Data. “Import Alerts by Publish Date.” Import Alert 66‑80 (published June 4, 2026). https://www.accessdata.fda.gov/cms_ia/iapublishdate.html

Medical disclaimer: This article is for educational purposes only and is not medical advice. GLP‑1 medications and compounded products can carry serious risks. Talk with a licensed clinician about treatment options and report adverse events to FDA MedWatch where appropriate.

Sources & References

1. FDA PCAC Meeting Announcement (July 23-24, 2026)
2. PBS: FDA to Weigh Easing Limits on Peptides Favored by RFK Jr.
3. BioPharma Dive: FDA Peptides RFK Advisory Committee Restrictions
4. RAPS: FDA Considers Adding a Dozen Peptides to Bulk Drug List
5. Ars Technica: RFK Jr. Forces FDA to Reconsider 12 Peptides
6. ProPublica: Peptide Safety Investigation
7. New York Times: Peptide Ban FDA RFK Jr.
8. SSRP Institute: FDA Announces Change in Status of 12 Peptides
9. CNBC: RFK Jr. Peptides Hims Hers GLP-1
10. USA Today: RFK Jr. FDA Peptides Explainer